Andere Sprachen Xenon Pharmaceuticals Inc.

Aktien

A12ETN

CA98420N1050

XENE

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:05:21 06.05.2024			% 5 Tage	% 1. Jan.
43,88 ^USD	+0,29 %		+2,32 %	-5,08 %

19.04.	Xenon Pharmaceuticals Inc. kündigt Rücktritt des Vorstands an	CI
11.03.	Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update	02.05.
Xenon Pharmaceuticals Inc. Announces Board Resignations	19.04.
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting	16.04.
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	10.04.
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference	04.04.
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days	12.03.
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days	12.03.
Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing	08.03.
Xenon Pharmaceuticals Insider Sold Shares Worth $601,615, According to a Recent SEC Filing	08.03.
Xenon Pharmaceuticals : Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission - Form 8-K	08.03.
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024	05.03.
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024	05.03.
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
Xenon Pharmaceuticals Q4 Net Loss Widens	29.02.
Xenon Pharmaceuticals: Q4 Earnings Snapshot	29.02.
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	29.02.
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.02.
Certain Common Shares of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	27.02.
Certain Warrants of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	27.02.
Certain Options of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Xenon Pharmaceuticals Inc.

Aktien

A12ETN

CA98420N1050

XENE

Andere Sprachen

Filter